| 78739-0 |
Platelet aggregation.ristocetin induced^low dose |
ACnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Platelet aggregation ristocetin induced [Units/volume] in Blood --Low dose |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
COAG |
|
78739-0 |
|
|
|
|
Both |
|
|
|
0 |
PA Rist lo dose Bld-aCnc |
|
|
|
|
|
Agg; Aggr; Arbitrary concentration; Blood; COAGULATION; Hematology; Heme; lo dose; PA; PA Rist; Pl; Platelets; Platelt; Plt; Point in time; QNT; Quan; Quant; Quantitative; Random; RIPA; Thrombocyte; Thrombocytes; WB; Whole blood |
2.68 |
2.54 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 7874-1 |
Ehrlichia canis Ab |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Ehrlichia canis Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
7874-1 |
|
|
|
|
Both |
|
|
|
0 |
E canis Ab Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; E canis; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; Tropical canine pancytopenia |
2.56 |
1.0h(2) |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 78740-8 |
Pathologic casts |
Naric |
Urine |
Pt |
Qn |
Automated count |
|
ACTIVE |
Pathologic casts [#/area] in Urine by Automated count |
|
MIN |
DefinitionDescription |
|
|
/HPF |
|
|
|
|
|
|
UA |
|
78740-8 |
|
Automated count |
|
|
Both |
|
|
|
0 |
Path casts #/area Ur Auto |
|
|
|
|
|
#/area; Auto; Automated detection; Cast; Elec; Elect; Electr; Kidney; Nephrology; Number areic; Path; Path casts; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; UA; UR; URINALYSIS; Urn |
2.54 |
2.54 |
|
|
|
|
|
|
|
/[HPF] |
|
|
|
0 |
| 78741-6 |
Pathologic casts |
NCnc |
Urine |
Pt |
Qn |
Automated count |
|
ACTIVE |
Pathologic casts [#/volume] in Urine by Automated count |
|
MIN |
DefinitionDescription |
|
|
/uL |
|
|
|
|
|
|
UA |
|
78741-6 |
|
Automated count |
|
|
Observation |
|
|
|
0 |
Path casts # Ur Auto |
|
|
|
|
|
#; ABS; absolute; absolutes; Auto; Automated detection; Cast; Cnt; Count; Count/volume; CT; Elec; Elect; Electr; Kidney; Nephrology; Number concentration; Number Concentration (count/vol); Path; Path casts; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; UA; UR; URINALYSIS; Urn |
2.54 |
2.54 |
|
|
|
|
|
|
|
/uL |
|
|
|
0 |
| 78742-4 |
Yeast |
Naric |
Urine |
Pt |
Qn |
Automated count |
|
ACTIVE |
Yeast [#/area] in Urine by Automated count |
|
MIN |
DefinitionDescription |
|
|
/HPF |
|
|
|
|
|
|
UA |
|
78742-4 |
|
Automated count |
|
|
Observation |
|
|
|
0 |
Yeast #/area Ur Auto |
|
|
|
|
|
#/area; Auto; Automated detection; Elec; Elect; Electr; ID; Infectious Disease; InfectiousDisease; Number areic; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; URINALYSIS; Urn |
2.73 |
2.54 |
|
|
|
|
|
|
|
/[HPF] |
|
|
|
0 |
| 78743-2 |
Steroid fractions interpretation |
Imp |
Urine |
Pt |
Nar |
|
|
ACTIVE |
Steroid fractions interpretation in Urine Narrative |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
78743-2 |
|
|
|
|
Observation |
|
|
|
0 |
Steroid Fract Ur-Imp |
|
|
|
|
|
Chemistry; Frac; Fract; Fraction; Fractionated; Fractionation; Impression; Impression/interpretation of study; Impressions; Interp; Interpret; Interpretation; Interpt; Intrp; Narrative; Point in time; Random; Report; UA; UR; Urn |
2.54 |
2.54 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 78744-0 |
Drug for further processing label |
- |
^FDA product label |
- |
Nar |
|
|
ACTIVE |
FDA product label Drug for further processing label |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOCUMENT.REGULATORY |
|
78744-0 |
|
|
|
|
Both |
|
|
|
0 |
FDA label Drug for further processing |
|
|
|
|
|
DOCUMENT.REGULATORY; Drugs; FDA label; Narrative; Report |
2.54 |
2.54 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 78745-7 |
Recombinant deoxyribonucleic acid construct label |
- |
^FDA product label |
- |
Nar |
|
|
ACTIVE |
FDA product label Recombinant deoxyribonucleic acid construct label |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DOCUMENT.REGULATORY |
|
78745-7 |
|
|
|
|
Both |
|
|
|
0 |
FDA label rDNA construct |
|
|
|
|
|
Acd; Acids; DOCUMENT.REGULATORY; FDA label; Narrative; rDNA construct; Report |
2.54 |
2.54 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 78746-5 |
Country of birth |
Loc |
^Patient |
Pt |
Nom |
|
|
ACTIVE |
Country of birth [Location] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ADMIN.PATIENT.DEMOG |
|
78746-5 |
|
|
|
|
Both |
|
|
|
0 |
Country of birth |
|
|
|
|
|
ADMIN; ADMIN.PATIENT; ADMIN.PT.DEMOG; Location; Nominal; Point in time; Random |
2.66 |
2.54 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 78747-3 |
Peritoneal equilibration test panel |
- |
Dial fld prt |
Pt |
- |
|
|
ACTIVE |
Peritoneal equilibration test panel - Peritoneal dialysis fluid |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
78747-3 |
|
|
|
|
Order |
|
|
|
0 |
PET Pnl DiafP |
|
|
|
|
|
Chemistry; Diaf; DiafP; Dialysate; Dialysis fluid; Pan; PANEL.CHEMISTRY; Panl; Peritoneal Dialysis fluid; PET Pnl; Pnl; Point in time; Random |
2.54 |
2.54 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 78748-1 |
Hemoglobin pattern |
Imp |
Bld |
Pt |
Nom |
Capillary electrophoresis |
|
ACTIVE |
Hemoglobin pattern [Interpretation] in Blood by Capillary electrophoresis (CE) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HEM/BC |
|
78748-1 |
|
Capillary electrophoresis |
|
|
Observation |
|
|
|
0 |
Hgb Fract Bld CE-Imp |
|
|
|
|
|
Blood; CE; Elec; Elect; Electr; Electro; Electrophhrs; Electrophrs; Elp; Elph; Ep; Haemoglobin; Hb; HEMATOLOGY/CELL COUNTS; Hgb; Hgb Fract; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Nominal; Point in time; Random; WB; Whole blood |
2.73 |
2.54 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 78749-9 |
Glycolate |
MCnc |
Ser/Plas |
Pt |
Qn |
GC |
|
ACTIVE |
Glycolate [Mass/volume] in Serum or Plasma by Gas chromatography |
|
ADD |
DefinitionDescription |
|
|
mg/dl |
|
|
|
|
|
|
CHEM |
|
78749-9 |
|
GC |
|
|
Both |
|
|
|
0 |
Glycolate SerPl GC-mCnc |
|
|
|
|
|
Chemistry; Gas chromatography; Glycolic acid; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.54 |
2.54 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 7875-8 |
Ehrlichia chaffeensis Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
IA |
|
ACTIVE |
Ehrlichia chaffeensis IgG Ab [Units/volume] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
7875-8 |
|
IA |
|
|
Both |
|
|
|
0 |
E chaffeensis IgG Ser IA-aCnc |
|
|
|
Y |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; E chaffeensis; EIA; ELFA; ELISA; Enzyme immunoassay; HME; Human monocytic ehrlichiosis; IAA; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; MEIA; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; SUDS |
2.69 |
1.0h(2) |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 78750-7 |
Hepatitis E virus RNA |
LaCnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Hepatitis E virus RNA [log units/volume] (viral load) in Serum or Plasma by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
log IU/mL |
|
|
|
|
|
|
MICRO |
|
78750-7 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HEV RNA SerPl NAA+probe-Log IU |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; DNA NUCLEIC ACID PROBE; DNA probe; Hep; Hep E; Hepatis; Hepatit; Hepatology; HEV; HEV RNA; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Liver; Log ACNC; Log IU; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; Viral load |
2.73 |
2.54 |
|
|
|
|
|
|
|
{Log_IU}/mL |
|
|
|
0 |
| 78751-5 |
11-Hydroxy delta-9 tetrahydrocannabinol |
MCnt |
Hair |
Pt |
Qn |
|
|
ACTIVE |
11-Hydroxy delta-9 tetrahydrocannabinol [Mass/mass] in Hair |
|
ADD |
DefinitionDescription |
|
|
pg/mg |
|
|
|
|
|
|
DRUG/TOX |
|
78751-5 |
|
|
|
|
Both |
|
|
|
0 |
11OH-THC Hair-mCnt |
|
|
|
|
|
11-hydroxy-delta(9)-THC; 11-hydroxytetrahydrocannabinol; 11-hydroxy-THC; 11-OH-THC; 11OH-THC; 7-hydroxy-delta(1)-tetrahydrocannabinol; Delta(9)-THC; Delta-9-tetrahydrocannabinol; Delta-9-tetrahydrocannabinol metabolite; Dronabinol; DRUG/TOXICOLOGY; Drugs; Har; Hydrox; Marijuana; Mass content; Nabilone; OH; Point in time; QNT; Quan; Quant; Quantitative; Random; THC; THC metabolite |
2.54 |
2.54 |
|
|
|
|
|
|
|
pg/mg |
|
|
|
0 |
| 78752-3 |
11-Hydroxy delta-9 tetrahydrocannabinol |
PrThr |
Body fld |
Pt |
Ord |
Screen |
|
ACTIVE |
11-Hydroxy delta-9 tetrahydrocannabinol [Presence] in Body fluid by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
78752-3 |
|
Screen |
|
|
Both |
|
|
|
0 |
11OH-THC Fld Ql Scn |
|
|
|
|
|
11-hydroxy-delta(9)-THC; 11-hydroxytetrahydrocannabinol; 11-hydroxy-THC; 11-OH-THC; 11OH-THC; 7-hydroxy-delta(1)-tetrahydrocannabinol; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Delta(9)-THC; Delta-9-tetrahydrocannabinol; Delta-9-tetrahydrocannabinol metabolite; Dronabinol; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Hydrox; Marijuana; Nabilone; OH; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; THC; THC metabolite |
2.58 |
2.54 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 78753-1 |
11-Hydroxy delta-9 tetrahydrocannabinol |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
11-Hydroxy delta-9 tetrahydrocannabinol [Presence] in Serum or Plasma by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
78753-1 |
|
Screen |
|
|
Both |
|
|
|
0 |
11OH-THC SerPl Ql Scn |
|
|
|
|
|
11-hydroxy-delta(9)-THC; 11-hydroxytetrahydrocannabinol; 11-hydroxy-THC; 11-OH-THC; 11OH-THC; 7-hydroxy-delta(1)-tetrahydrocannabinol; Delta(9)-THC; Delta-9-tetrahydrocannabinol; Delta-9-tetrahydrocannabinol metabolite; Dronabinol; DRUG/TOXICOLOGY; Drugs; Hydrox; Marijuana; Nabilone; OH; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; THC; THC metabolite |
2.56 |
2.54 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 78754-9 |
11-Hydroxy delta-9 tetrahydrocannabinol |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
11-Hydroxy delta-9 tetrahydrocannabinol [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
78754-9 |
|
Screen |
|
|
Both |
|
|
|
0 |
11OH-THC Ur Ql Scn |
|
|
|
|
|
11-hydroxy-delta(9)-THC; 11-hydroxytetrahydrocannabinol; 11-hydroxy-THC; 11-OH-THC; 11OH-THC; 7-hydroxy-delta(1)-tetrahydrocannabinol; Delta(9)-THC; Delta-9-tetrahydrocannabinol; Delta-9-tetrahydrocannabinol metabolite; Dronabinol; DRUG/TOXICOLOGY; Drugs; Hydrox; Marijuana; Nabilone; OH; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; THC; THC metabolite; UA; UR; Urn |
2.56 |
2.54 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 78755-6 |
1-Hydroxymidazolam |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
1-Hydroxymidazolam [Mass/volume] in Blood |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
78755-6 |
|
|
|
|
Both |
|
|
|
0 |
1OH-midazolam Bld-mCnc |
|
|
|
|
|
1-Hydroxy midazolam; 1OH-midazolam; Alpha hydroxymidazolam; Alpha-hydroxymidazolam; Blood; Chlonazepam metabolite; DRUG/TOXICOLOGY; Drugs; i; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.54 |
2.54 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 78756-4 |
2-Oxo-3-Hydroxy-Lysergate diethylamide |
PrThr |
Bld |
Pt |
Ord |
Screen |
|
ACTIVE |
2-Oxo-3-Hydroxy-Lysergate diethylamide [Presence] in Blood by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
78756-4 |
|
Screen |
|
|
Both |
|
|
|
0 |
2-oxo-3-OH-LDS Bld Ql Scn |
|
|
|
|
|
2-oxo-3-OH-LDS; Blood; DRUG/TOXICOLOGY; Drugs; Hydrox; II; III; LSD; LSD metabolite; Lysergic acid; Lysergic acid diethylamide; OH; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; WB; Whole blood |
2.56 |
2.54 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 78757-2 |
2-Oxo-3-Hydroxy-Lysergate diethylamide |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
2-Oxo-3-Hydroxy-Lysergate diethylamide [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
78757-2 |
|
Screen |
|
|
Both |
|
|
|
0 |
2-oxo-3-OH-LDS Ur Ql Scn |
|
|
|
|
|
2-oxo-3-OH-LDS; DRUG/TOXICOLOGY; Drugs; Hydrox; II; III; LSD; LSD metabolite; Lysergic acid; Lysergic acid diethylamide; OH; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; UA; UR; Urn |
2.56 |
2.54 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 78758-0 |
4-Hydroxymidazolam |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
4-Hydroxymidazolam [Mass/volume] in Urine |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
78758-0 |
|
|
|
|
Both |
|
|
|
0 |
4OH-midazolam Ur-mCnc |
|
|
|
|
|
4-Hydroxy midazolam; 4OH-midazolam; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Midazolam metabolite; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.54 |
2.54 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 78759-8 |
6-Monoacetylmorphine |
PrThr |
Bld |
Pt |
Ord |
Screen |
|
ACTIVE |
6-Monoacetylmorphine (6-MAM) [Presence] in Blood by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
78759-8 |
|
Screen |
|
|
Both |
|
|
|
0 |
6MAM Bld Ql Scn |
|
|
|
|
|
6 MAM; 6 mono acetyl morphine; 6-acetylmorphine; 6MAM; Acetylmorphine; Addiction; Blood; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Heroin metabolite; Illicit; MAM; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; WB; Whole blood |
2.56 |
2.54 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 7876-6 |
Ehrlichia chaffeensis Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Ehrlichia chaffeensis IgM Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
7876-6 |
|
|
|
|
Both |
|
|
|
0 |
E chaffeensis IgM Ser Ql |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; E chaffeensis; HME; Human monocytic ehrlichiosis; ID; Immune globulin M; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR |
2.73 |
1.0h(2) |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 78760-6 |
6-Monoacetylmorphine |
PrThr |
Body fld |
Pt |
Ord |
Screen |
|
ACTIVE |
6-Monoacetylmorphine (6-MAM) [Presence] in Body fluid by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
78760-6 |
|
Screen |
|
|
Both |
|
|
|
0 |
6MAM Fld Ql Scn |
|
|
|
|
|
6 MAM; 6 mono acetyl morphine; 6-acetylmorphine; 6MAM; Acetylmorphine; Addiction; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Fl; Fld; FLU; Fluid; Heroin metabolite; Illicit; MAM; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn |
2.58 |
2.54 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
